US sales forecasts look good for Lundbeck's new antidepressant drug  

J P Morgan Chase forecasts sales of DKK 20 billion for Lundbeck's antidepressant drugs over next 4 years
According to the US investment bank J P Morgan Chase, US sales of Lundbeck's antidepressant drugs are forecast to approach DKK 20 billion (USD 2.6 billion) over the next 4 years. The calculation is based on July-September results released by Lundbeck's US cooperation partner Forest Labs on Tuesday. Sales of Lundbeck's newly introduced SSRI Lexapro (escitalopram) are forecast to account for DKK 18.4 billion (USD 2.4 billion) of the 4 year prospective total, with the company's predecessor SSRI drug Celexa (citalopram) accounting for the remainder. The Lundbeck Group is expected to generate a turnover in the current year of DKK 10 billion (USD 1.3 billion), including estimated royalty payments from Forest Labs. The news is reported in Jyllands-Posten today.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×